Prognositc Factors in COVID-19 Patients Complicated With Hypertension

Study Overview
=================
Brief Summary
-----------------
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

Detailed Description
-----------------
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology. Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo. A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.

Official Title
-----------------
Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China

Conditions
-----------------
2019-nCoV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult aged >=18years old; Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia. Diagnosed with primary hypertension. Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg. Exclusion Criteria: Near-death state (expected survival time less than 24 hours); Malignant tumor; Pregnancy or puerperium women; ACEI contraindication Patients who refused to participant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ACEI treatment<br>hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China | |
| Control<br>hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occupancy rate in the intensive care unit (ICU) | The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19. | up to 28 days | 
| Mechanical Ventilation | The number of patients requiring mechanical ventilation. | up to 28 days | 
| Death | The number of patients who died of 2019-nCoV infection. | up to 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality | The number of died 2019-nCoV infected patients from any cause. | up to 28 days | 
| Time from onset of symptoms to main outcome and its components | Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death. | up to 28 days | 
| Time to Clinical Recovery | Time to Clinical Recovery | up to 28 days |